Barclays PLC Adc Therapeutics Sa Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Barclays PLC holds 101,034 shares of ADCT stock, worth $199,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,034

Previous 141,495 28.6%

Holding current value

$199,036

Previous $282,000 49.65%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.39 - $2.02 $56,240 - $81,731	-40,461 Reduced 28.6%	101,034 $142,000
Q4 2024 Feb 13, 2025	BUY	$1.89 - $3.48 $25,998 - $47,870	13,756 Added 10.77%	141,495 $282,000
Q3 2024 Nov 15, 2024	BUY	$2.59 - $4.01 $243,175 - $376,498	93,890 Added 277.38%	127,739 $402,000
Q2 2024 Aug 14, 2024	BUY	$2.55 - $5.09 $86,314 - $172,291	33,849 New	33,849 $107,000
Q2 2023 Aug 03, 2023	SELL	$1.9 - $2.66 $36,759 - $51,463	-19,347 Reduced 5.79%	314,925 $677,000
Q1 2023 May 04, 2023	BUY	$1.92 - $5.45 $641,802 - $1.82 Million	334,272 New	334,272 $652,000

Others Institutions Holding ADCT

# of Institutions

Shares Held

53.9M

Call Options Held

Put Options Held

7.6K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $153M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account